Home
Drugs
Pertuzumab
Clinical Trials

Clinical Trials Related to Pertuzumab

Related studies linked through entity extraction aliases.

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Status: RECRUITING
Phase: PHASE2

ctDNA in HER2+ EBC Neoadjuvant Treatment

Status: RECRUITING
Phase: PHASE2

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Status: NOT_YET_RECRUITING
Phase: NA

HB1801 Combined Treatment of HER2-positive Breast Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Status: RECRUITING
Phase: PHASE2

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE4

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Status: NOT_YET_RECRUITING
Phase: PHASE2

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Status: RECRUITING
Phase: PHASE2

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Status: RECRUITING
Phase: PHASE2/PHASE3

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Status: RECRUITING
Phase: PHASE3

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Status: RECRUITING
Phase: PHASE1/PHASE2

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

Status: NOT_YET_RECRUITING
Phase: PHASE2

The Sagittarius Trial

Status: RECRUITING
Phase: PHASE3

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

Status: RECRUITING
Phase: PHASE2

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Status: RECRUITING
Phase: PHASE2

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Status: RECRUITING
Phase: PHASE3

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study

Status: RECRUITING
Phase: PHASE1